Merck & Co. Inc.'s Keytruda (pembrolizumab) has secured a new tumor-agnostic indication from the US Food and Drug Administration for patients with unresectable or metastatic tumor mutational burden-high (TMB-H) solid tumors. Other PD-1/L1 inhibitors, including Bristol-Myers Squibb Co.'s Opdivo (nivolumab) and AstraZeneca PLC's Imfinzi (durvalumab) have both pursued high TMB in lung cancer without success.
The 16 June FDA approval was an accelerated approval based on retrospective analysis of data from 10 cohorts of patients with previously treated unresectable or metastatic solid tumors with TMB-H in KEYNOTE-158; continued approval may be contingent on confirmatory study results
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?